REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Within the Basic Sciences Division, researchers have bonded over their admiration for Caenorhabditis elegans (C. elegans), a ...
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...